FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAquestive Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AQST
Aquestive Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Aquestive Therapeutics, Inc. (AQST) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAQST
AQST
Aquestive Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AQST
  1. Home
  2. Stocks
  3. Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc.

🇺🇸AQST•NASDAQ

Aquestive Therapeutics, Inc.

🇺🇸AQST•NASDAQ
Market cap
$472.59M
Sentiment

Your view on AQST

Mkt Cap
$472.59M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Aquestive Therapeutics, Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Daniel Barber
Headquarters
30 Technology Drive, Warren, NJ, US
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Daniel Barber
Headquarters
30 Technology Drive, Warren, NJ, US
Description

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally.

The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis.

Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis.

Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Aquestive Therapeutics, Inc. from FRC's valuation model, read against the market price. AQST last traded at $3.76; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Aquestive Therapeutics, Inc.. Starting points for Aquestive Therapeutics, Inc.: EPS -$0.63, beta 1.50 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Aquestive Therapeutics, Inc.. Aquestive Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Aquestive Therapeutics, Inc.. Trailing twelve-month EPS for Aquestive Therapeutics, Inc. stands at -$0.63. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 17, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$9.75

average of 4 firms, last 12 months

 

$9.75

Low $6.00

Median $10.50

High $12.00

 

Analyst Ratings

Buy10 ratings
  • Strong Buy0
  • Buy10
  • Hold0
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate-$0.11-$0.13-$0.47-$0.49
Low estimate-$0.13-$0.17-$0.52-$0.62
High estimate-$0.09-$0.11-$0.44-$0.40
No. of analysts2144
Year-ago EPS-$0.261-$0.07-$0.761—
Growth—-83.3%——

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$13.70M$12.43M$49.50M$67.91M
Low estimate$13.04M$11.88M$48.71M$64.49M
High estimate$14.89M$12.98M$50.29M$72.81M
No. of analysts6367
Year-ago revenue$13.02M$14.45M$44.55M—
Growth+5.2%-14.0%+11.1%—
Recent analyst actions15 rating and price-target changes, latest Oct 16, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 17, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Aquestive Therapeutics, Inc.. Aquestive Therapeutics, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold AQST20 companies · 8 funds
Compare AQST with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ALKSAlkermes plcDrug Manufacturers - Specialty & Generic$7.8B
  • AMPHAmphastar Pharmaceuticals, Inc.Drug Manufacturers - Specialty & Generic$1.2B
  • AYTUAytu BioPharma, Inc.Drug Manufacturers - Specialty & Generic$20M
  • COLLCollegium Pharmaceutical, Inc.Drug Manufacturers - Specialty & Generic$790M
  • CPIXCumberland Pharmaceuticals Inc.Drug Manufacturers - Specialty & Generic$78M
  • DERMJourney Medical CorporationDrug Manufacturers - Specialty & Generic$104M
  • SUPNSupernus Pharmaceuticals, Inc.Drug Manufacturers - Specialty & Generic$6.0B
  • VNDAVanda Pharmaceuticals Inc.Biotechnology$230M

More Drug Manufacturers - Specialty & Generic companies

  • NPPNYNippon Shinyaku Co., Ltd.OTC$2.3B
  • NSRSNorth Springs Resources CorpOTC$35,902
  • NUGSCannabis Strategic VenturesOTC$187,588
  • NXENNexien BioPharma, Inc.OTC$7,077
  • OGIOrganigram Global Inc.NASDAQ$102M
  • OGI.TOOrganiGram Holdings Inc.TSX$147M
  • OILFFNextleaf Solutions Ltd.OTC$6M
  • OILS.CNNextleaf Solutions Ltd.CNQ$8M
  • OMIDOMID Holdings, Inc.OTC
  • OPTHOptimi Health Corp.NASDAQ$13M
  • OPTI.CNOptimi Health Corp.CNQ$27M
  • ORGOOrganogenesis Holdings Inc.NASDAQ$104M

ETFs holding Aquestive Therapeutics, Inc.

% of the fund

  • IWMiShares Russell 2000 ETF$76.6B in assets0.01%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
  • XPHState Street SPDR S&P Pharmaceuticals ETF$516M in assets0.99%
  • VXFVanguard Extended Market ETF$30.2B in assets0.01%
  • SURISimplify Propel Opportunities ETF$70M in assets1.53%
  • FSCCFederated Hermes MDT Small Cap Core ETF$496M in assets0.24%
  • IWCiShares Micro-Cap ETF$1.2B in assets0.11%
  • VTWVVanguard Russell 2000 Value ETF$1.3B in assets0.02%

Largest holders first, then the funds most concentrated in AQST.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Aquestive Therapeutics, Inc., and how their positions are changing. At a $472.6M market value, institutional positions materially move Aquestive Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Aquestive Therapeutics, Inc. executives and directors. Shares of Aquestive Therapeutics, Inc. have traded between $2.12 and $7.55 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Aquestive Therapeutics, Inc.. Coverage tracks Aquestive Therapeutics, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Aquestive Therapeutics, Inc.

AQST Analysis
Weak
Past1
Growth1
Health1
Profit1
Value1

News

Latest Market News